XARELTO ® (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Heart | Peripheral Vascular Disease (PVD) | Pharmaceuticals | Study